Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Apr:43 Suppl 1:2S28-2S33.
doi: 10.1016/S1262-3636(17)30070-8.

GLP-1 receptor agonists in NAFLD

J-M Petit  1 , B Vergès  2
Affiliations
Review

GLP-1 receptor agonists in NAFLD

J-M Petit et al. Diabetes Metab. 2017 Apr.

Abstract

Non-alcoholic fatty liver disease (NAFLD) is very common in patients with type 2 diabetes (T2D), with approximately two-thirds having a diagnosis of the disease. Currently, the only validated treatment for NAFLD is weight loss. A number of studies of animal models and human trials have evaluated the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on liver fat content and suggest that the treatment could represent a new alternative for NAFLD management. In this review, our focus is on the main studies regarding the effects of GLP-1RAs on NAFLD. Also, the mechanisms that might explain their beneficial effects on liver diseases are analyzed.

Keywords: Fibrosis; GLP-1 receptor agonists; Non-alcoholic fatty liver disease; Steatosis; type 2 diabetes.

PubMed Disclaimer

MeSH terms

Substances